%0 Journal Article
%T Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer
%A Hyungshin Yim
%A Sang-Uk Woo
%A Sol-Bi Shin
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2019
%R 10.1177/1758835919846375
%X Despite the clinical success of taxanes, they still have limitations, such as chemoresistance. To overcome the limitations of paclitaxel, genetic alterations and targeting effects of altered genes were observed in paclitaxel-resistant cancer. Because paclitaxel-resistant cancer shows high levels of Plk1, a promising target in chemotherapy, the effectiveness of Plk1 inhibitors in paclitaxel-resistant cancer cells has been investigated
%K androgen receptor
%K paclitaxel
%K Plk1
%K resistance
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515847/